Sensitivity to extrinsically supplied interferon and the endogenous expression of interferon in melanoma cell lines

Melanoma Research

Volumn 9, Issue 5, 1999, Pages 451-456

  Hanson, C ^a   Kopf I ^a   Weijdegard B ^a   Welmarck, A ^a   Stierner, U ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Gene expression; Interferon; Melanoma; Reverse transcription polymerase chain reaction (RT PCR)

Indexed keywords

ALPHA INTERFERON; BETA ACTIN; BETA INTERFERON; CYCLOPHILIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INTERFERON RECEPTOR; MESSENGER RNA; RNA 18S;

ARTICLE; CANCER IMMUNOTHERAPY; CHEMOSENSITIVITY; CHROMOSOME 9P; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE EXPRESSION; GENE LOCATION; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; MULTIGENE FAMILY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

EID: 0007002082     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199910000-00004     Document Type: Article

References (14)

1. Kirkwood JM, Ernstoff MS. Hole of interferons in the therapy of melanoma. J Invest Dermatol 1990: 95(suppl 6): 180S-184S.
2. de Waard-Siebinga I, Creyghton WM, Kool J, Jager MJ. Effects of interferon alfa and gamma on human uveal melanoma cells in vitro. Br J Ophthalmol 1995; 79: 847-855.
3. Garrison JI, Berens ME, Rankin Shapiro J, Treasurywala S, Floyd-Smith G. Interferon-β inhibits proliferation and progression through S phase of the cell cycle in five glioma cell lines. J Neurooncol 1996; 30: 213-223.
4. Kirkwood JM, Melanoma. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Biologic Therapy of Cancer: Principles and Practice. Philadelphia: JB Lippincott, 1995: 388-411.
5. Buzaid AC, Legha SS. Combination of chemotherapy with interleukin-2 and interferon-alfa for the treatment of advanced melanoma. Semin Oncol 1994; 21: 23-28.
6. Punt CJA. The use of interferon-α in the treatment of cutaneous melanoma: a review. Melanoma Res 1998; 8: 95-104.
7. Kirkwood JM, Hunt Strawderman M, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14(1): 7-17.
8. Johns TG, Mackay IR, Callister KA, Hertzog PJ, Devenish RJ, Linnane AW. Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon β. J Natl Cancer Inst 1992; 84(15): 1185-1190.
9. Köpf I, Hanson C, Delle U, Weimarck A, Stierner U. Action of Interferon alpha and beta on four human melanoma cell lines in vitro Anticancer Res 1996; 16(2): 791-798.
10. Köpf I, Stierner U, Islam Q, Delle U, Kindblom L-G, Martinsson T. Characterization of four melanoma cell lines with electron microscopy, immunocytochemistry, cytogenetics, flow cytometry, and southern analysis. Cancer Genet Cylogenet 1992; 62(2): 111-123.
11. Chomczynski P, Sacchi N. Single-step method of RNA Isolation by acid quanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
12. Gomi K, Akinaga S, Oka T, Morimoto M. Analysis of receptors, cell surface antigens, and proteins In human melanoma cell lines resistant to human recombinant β- or γ-interferon. Cancer Res 1986; 46: 6211-6216.
13. Payne MJ, Ralph SJ, De Veer MJ, Allen K, Linnane AW, Devenish RJ. cDNA sequence identity for the type I Interferon receptor subunit from cell lines of widely differing responsiveness to interferon. Biochem Mol Biol Int 1994; 33(2): 283-288.
14. Grandér D, Einhorn S. Interferon and malignant disease how does it work and why doesn't it always? Acta Oncol 1998; 37(4): 331-338.